Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BIIB Biogen	$134.15 +0.8%	$122.85	$110.04 ▼ $238.00	$19.66B	0.14	1.41 million shs	1.08 million shs
DXCM DexCom	$85.68 -1.1%	$76.73	$57.52 ▼ $118.80	$33.60B	1.46	4.31 million shs	2.07 million shs
HLN Haleon	$10.88 -1.7%	$10.51	$8.25 ▼ $11.42	$48.99B	0.31	8.78 million shs	15.09 million shs
SGEN Seagen	$228.74	$228.74	$123.77 ▼ $228.96	$42.93B	0.32	1.48 million shs	86 shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BIIB Biogen	+0.77%	+2.30%	+13.49%	-6.62%	-40.49%
DXCM DexCom	-1.14%	+0.20%	+1.20%	+21.95%	-26.00%
HLN Haleon	-1.72%	-4.69%	+1.21%	+4.67%	+27.70%
SGEN Seagen	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BIIB Biogen	4.6667 of 5 stars	4.2	3.0	0.0	3.7	2.1	1.7	1.9
DXCM DexCom	4.7601 of 5 stars	3.5	4.0	0.0	4.7	2.4	2.5	1.9
HLN Haleon	3.0364 of 5 stars	2.4	5.0	2.5	0.0	3.3	0.0	1.3
SGEN Seagen	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BIIB Biogen	2.38	Hold	$191.30	42.60% Upside
DXCM DexCom	2.95	Moderate Buy	$98.32	14.75% Upside
HLN Haleon	2.73	Moderate Buy	$12.33	13.28% Upside
SGEN Seagen	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest HLN, BIIB, SGEN, and DXCM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/30/2025	DXCM DexCom	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$104.00
5/27/2025	HLN Haleon	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/27/2025	HLN Haleon	BNP Paribas Exane Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Outperform	$13.40
5/22/2025	DXCM DexCom	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$82.00 ➝ $102.00
5/9/2025	HLN Haleon	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$11.25
5/7/2025	BIIB Biogen	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$207.00 ➝ $169.00
5/6/2025	HLN Haleon	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
5/5/2025	BIIB Biogen	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$185.00 ➝ $175.00
5/5/2025	DXCM DexCom	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$90.00 ➝ $93.00
5/2/2025	BIIB Biogen	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$205.00
5/2/2025	BIIB Biogen	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$217.00 ➝ $205.00

(Data available from 6/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BIIB Biogen	$9.82B	2.00	$22.03 per share	6.09	$114.71 per share	1.17
DXCM DexCom	$4.15B	8.10	$2.16 per share	39.75	$5.38 per share	15.93
HLN Haleon	$11.23B	4.36	$0.40 per share	27.07	$4.51 per share	2.41
SGEN Seagen	$2.30B	18.66	N/A	N/A	$15.10 per share	15.15

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BIIB Biogen	$1.63B	$10.13	11.99	8.13	1.51	16.87%	14.98%	8.76%	7/30/2025 (Estimated)
DXCM DexCom	$576.20M	$1.34	59.92	34.83	2.30	14.29%	30.14%	10.11%	7/24/2025 (Estimated)
HLN Haleon	$1.30B	$0.39	32.00	22.20	2.82	10.85%	14.76%	7.32%	6/11/2025 (Estimated)
SGEN Seagen	-$610.31M	-$4.01	N/A	N/A	N/A	-32.61%	-28.06%	-20.92%	N/A

Latest HLN, BIIB, SGEN, and DXCM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/1/2025	Q1 2025	BIIB Biogen	$3.26	$3.02	-$0.24	$1.64	$2.25 billion	$2.43 billion
5/1/2025	Q1 2025	DXCM DexCom	$0.33	$0.32	-$0.01	$0.27	$1.02 billion	$1.04 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
DXCM DexCom	N/A	N/A	N/A	N/A	N/A
HLN Haleon	$0.24	2.21%	N/A	61.54%	N/A
SGEN Seagen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BIIB Biogen	0.27	1.35	0.90
DXCM DexCom	0.59	1.47	1.28
HLN Haleon	0.44	0.84	0.58
SGEN Seagen	N/A	2.67	2.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BIIB Biogen	87.93%
DXCM DexCom	97.75%
HLN Haleon	6.67%
SGEN Seagen	84.26%

Insider Ownership

Company	Insider Ownership
BIIB Biogen	0.18%
DXCM DexCom	0.32%
HLN Haleon	N/A
SGEN Seagen	25.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BIIB Biogen	8,720	146.53 million	146.14 million	Optionable
DXCM DexCom	7,600	392.11 million	389.60 million	Optionable
HLN Haleon	25,408	4.50 billion	N/A	Not Optionable
SGEN Seagen	3,256	187.70 million	139.08 million	Optionable

HLN, BIIB, SGEN, and DXCM Headlines

Recent News About These Companies

Trial win sets up new use for Astellas, Seagen's Padcev in bladder cancer

March 16, 2025 | pharmaphorum.com

Merck in "advanced talks" for $40bn Seagen bid; report

March 7, 2025 | pharmaphorum.com

Seagen posts breast cancer win ahead of Pfizer takeover

February 23, 2025 | pharmaphorum.com

Is Merck planning a $30bn-plus move for Seagen?

December 6, 2024 | pharmaphorum.com

Pfizer raises guidance as COVID franchise drives Q3 beat

October 30, 2024 | seekingalpha.com

Pfizer Delivers Knockout Q3 Earnings Results, But Investors Are Unimpressed

October 30, 2024 | seekingalpha.com

Franklin Biotechnology Discovery C

October 5, 2024 | morningstar.com

Seagen wins Enhertu patent dispute with Daiichi Sankyo

July 20, 2024 | pharmaphorum.com

Pfizer: Turning The Corner (Rating Upgrade)

May 27, 2024 | seekingalpha.com

Two Brothers, a Big Biotech Bet and an $8 Billion Payout

April 13, 2024 | wsj.com

HER2 heats up as Seagen licenses RemeGen ADC for $2.6bn

April 2, 2024 | pharmaphorum.com

Ron Baron Portfolio Magic: Building Your Financial Future

March 20, 2024 | msn.com

Bailouts are back, Fed outlook reassessed, Pfizer M&A - what's moving markets

March 13, 2024 | msn.com

Pfizer shutting down Seagen's $350M construction project in Everett

March 1, 2024 | bizjournals.com

Neuralink’s First Brain Implant Patient Can Control Mouse with Thoughts, Musk Says

February 24, 2024 | finance.yahoo.com

MRNA Feb 2024 64.000 put

February 23, 2024 | finance.yahoo.com

MRNA Feb 2024 77.000 call

February 23, 2024 | finance.yahoo.com

Pfizer adds bull at Guggenheim on ex-COVID prospects

February 23, 2024 | msn.com

MRNA Feb 2024 67.000 put

February 22, 2024 | finance.yahoo.com

Pfizer touts cancer efforts in first Super Bowl commercial

February 12, 2024 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HLN, BIIB, SGEN, and DXCM Company Descriptions

Biogen NASDAQ:BIIB

$134.15 +1.02 (+0.77%)

Closing price 06/9/2025 04:00 PM Eastern

Extended Trading

$137.01 +2.86 (+2.13%)

As of 04:01 AM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

DexCom NASDAQ:DXCM

$85.68 -0.99 (-1.14%)

Closing price 06/9/2025 04:00 PM Eastern

Extended Trading

$85.30 -0.38 (-0.44%)

As of 04:00 AM Eastern

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Haleon NYSE:HLN

$10.88 -0.19 (-1.72%)

Closing price 06/9/2025 03:59 PM Eastern

Extended Trading

$10.91 +0.03 (+0.28%)

As of 06/9/2025 07:52 PM Eastern

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.

Seagen NASDAQ:SGEN

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time